Physitrack (PTRK) Q2 2026 earnings summary

Executive summary

• Revenue grew 8% year-on-year to €3.4m in Q2 2026, with 96% from subscriptions and Lifecare division driving growth; ARPL increased 10% to €189, churn stable at 1%.

• Adjusted EBITDA was €1.2m (34% margin), stable quarter-on-quarter but down from 38% a year ago due to North American investment and RTM launch.

• Wellness division returned to profitability, with adjusted EBITDA margin at 32% after restructuring and OPEX reduced by 41% YoY.

• Net profit after tax from continuing operations was €49k in Q2; positive operating cash flow for the seventh consecutive quarter.

• Major milestones included the US launch of RTM, first paying customers, and a non-dilutive share buyback program.

Financial highlights

• Revenue reached €3.4m in Q2 2026, up 8% YoY and 6% QoQ; YTD revenue €6.7m (+5% YoY).

• Adjusted EBITDA was €1.2m (34% margin, -4pp YoY); free cash flow (excluding legal settlement) was €0.1m.

• Group ARR reached €13.6m (+7% QoQ, +3% YoY); SaaS gross margin in Lifecare remained strong at 90%.

• Net debt increased to €3.9m, reflecting legal settlement and facility drawdown; available liquidity at 30 June 2026 was €1.7m.

• Net profit after tax from continuing operations: €48.9k (Q2), €107.3k (YTD).

Outlook and guidance

• CapEx cycle expected to moderate in H2 as RTM build completes; focus on scaling RTM adoption and progressing enterprise tenders in Europe and the US.

• Medium-term EBITDA margin target remains 40%-45%, with margin expansion expected through revenue growth.

• Management expects H1 2026 investments to drive accelerating ARR growth in H2 2026 and beyond.

• No capital raise anticipated in the next 12 months; organic growth target for 2027 is 20%-30%.

• Wellness division to complete transition to scalable enterprise SaaS, replacing legacy contracts.